Anixa Biosciences (ANIX) Corporate presentation summary

Business overview

• Clinical-stage company focused on developing first-in-class products for cancer treatment and prevention.

• Maintains a strong balance sheet with $14M in cash and no debt as of July 31, 2026.

• Operates a capital-efficient model with low annual cash burn and consistent insider buying.

• Engages in key partnerships with leading research institutions for program development.

• Targets significant total addressable markets in oncology.

Financial highlights

• Cash and short-term investments total $14M as of July 31, 2026.

• Annual cash burn has been approximately $5-7M since 2017, with $7M in the last fiscal year.

• No debt, warrants, or preferred stock; 35M common shares outstanding.

• Business model leverages partnerships to minimize overhead and enable multiple projects.

Clinical pipeline and partnerships

• Two clinical-stage programs: CAR-T therapy for ovarian cancer and a breast cancer vaccine.

• Programs developed in collaboration with Moffitt Cancer Center, The Wistar Institute, and Cleveland Clinic.

• CAR-T program in Phase 1 for ovarian and other solid tumors; breast cancer vaccine completed Phase 1.

• Upcoming milestones include periodic data releases and Phase 2 enrollment.